ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has received further clinical testing results from BioScience Laboratories, Inc. for the T36(R) formulation ("T36(R)"). Complete efficacy was achieved against Candida albicans by T36(R) within the shortest time required by the FDA, Health Canada and the European Medicines Agency. C. albicans is a major cause of yeast infections which account for one-third of all vulvovaginal infections ("VVI's"). Bacteria are a second major cause of VVI's and combinations of bacteria and fungi cause most of the remaining cases. The effectiveness that T36(R) has demonstrated against both fungi and bacteria provides important evidence that ALDA's T36(R) VVI Treatment will provide an effective means to treat all types of VVI's.

Dr. Terrance Owen, President & CEO, states, "The positive test results that we have received on fungi and bacteria are very gratifying. We know that T36(R) is very effective, but it is essential that ALDA demonstrate this effectiveness under the rigourous conditions required by the pharmaceutical regulatory agencies in the US, Canada and the EU. This is another significant step forward for ALDA and brings us closer to our goal of developing treatments for a wide range of microbial infections."

These developments and others will be discussed in interviews with Dr. Owen on WallSt.net web site on Thursday, January 31 and CFRA Radio in Ottawa for their "Business@Night" program at 6:00 PM, also on January 31.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.

SOURCE: ALDA Pharmaceuticals Corp.